Navigation Links
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention

nistration. Furthermore, INO-1001 treatment was associated with a trend towards reduced levels of select inflammatory proteins, including C-reactive protein and interleukin-6. No-drug related serious adverse events were observed in the 30 patients receiving drug during the study period.

The Phase 2 trial was a prospective, single-blind, multi-center, dose-escalation study of a single dose of intravenous INO-1001 (200 mg, 400 mg, or 800 mg) administered in adults presenting with acute STEMI who were to be treated with primary PCI. The study enrolled 40 patients between the ages of 48 and 63. The primary endpoint of the study was to evaluate the safety, tolerability and pharmacokinetic profile of INO-1001. The secondary objectives of the study were to characterize the pharmacodynamic profile of INO-1001 and to evaluate various biomarkers of necrosis and inflammation.

About PARP Inhibitors

Poly (ADP-ribose) polymerase (PARP) is an abundant nuclear enzyme that mediates the repair of DNA single strand breaks through the activation and recruitment of DNA repair enzymes. PARP's role in the inflammatory response may result from its ability to potentiate the activity of key inflammatory transcription factors (NF-kappaB and AP-1). PARP inhibitors have shown promise in a variety of inflammatory and ischemia/reperfusion diseases, including those related to acute cardiovascular conditions. PARP inhibitors may also have potential application in cancer, and are being studied to ascertain their ability to block one of the key defense mechanisms that cancer cells rely upon to resist standard chemotherapy. By blocking tumor defenses, PARP therapy may increase the susceptibility of tumors to standard chemotherapy or even reverse tumor resistance.

About INO-1001

INO-1001 represents Inotek's lead candidate in a series of novel PARP inhibitors discovered by Inotek. In July 2006, Inotek and Genentech, Inc. entered into an exclusive global collaboration t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/30/2015)... -- Global ENT (Ear, Nose, And ... 23.01 million in 2022, according to a new study ... population, increasing prevalence of ear, nose, and throat related ... target customer base are expected serve this market as ... to estimates published by the WHO, 15% of adult ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud ... predictive analytics technology, announces it is working with ... solutions for the new Lockheed Martin Healthcare Technology ... leading health information technology providers, medical technology companies ... collaboration and innovation to improve care in rapidly ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 13, 2007 -,Cytos Biotechnology AG (SWX:CYTN) reported ... with CYT003-QbG10, an immunotherapeutic,product candidate for the ... patients suffering from mild to moderate allergic,rhinitis ... The trial,investigated in a doubleblind setting the ...
... company Pharmaxis today announced the results,from its Phase ... Pulmonary Disease (COPD), a respiratory disease,affecting over 30 ... in 79 diagnosed COPD patients at 12,centres in ... to,determine if subjects that were positive to an ...
Cached Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4
(Date:7/31/2015)... ... ... New Energy Works Timberframers invites the public to join their timber frame ... 9am – 12pm. Timber frame raisings are special, celebrating both craft and ... culmination of months of effort, planning, fundraising, and dreaming takes shape. , “There’s ...
(Date:7/31/2015)... ... 2015 , ... Super-Sod wants to participate in planning new home lawns from ... the perfect fit for such a goal. Houzz is a social media site that ... dynamic site that spreads home and home garden design ideas when members share their ...
(Date:7/31/2015)... DE (PRWEB) , ... July 31, 2015 , ... ... term care client base, with the recent implementation of Microsoft Dynamics GP for ... in the industry, Intellitec is now supporting senior living communities in 16 states. ...
(Date:7/30/2015)... ... , ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the ... Expo held at the Caribe Royal All Suites Hotel and Convention Center in Orlando, ... the largest medical cannabis expo in the country and this year’s expo will be ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, ... an app invention that can help people during emergencies. , "The worldwide mobile ... and Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile ...
Breaking Medicine News(10 mins):Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5
... HealthDay Reporter , WEDNESDAY, Oct. 27 (HealthDay ... the vaccine that protects against bacterial meningitis, a U.S. ... the recommendation because the vaccine appears not to last ... U.S. Centers for Disease Control and Prevention,s Advisory Committee ...
... develops and spreads much more slowly than scientists have ... The finding indicates that there is a potentially broad ... "For the first time, we have a quantifiable estimate ... would be best to intervene," according to Christine Iacobuzio-Donahue, ...
... planning of care and stronger relationships with physicians are ... a study by a Queen,s University professor. , "High ... Canadian," says professor of Medicine and Epidemiology Daren Heyland, ... "But it,s not always happening. We know from international ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With October ... offers breast cancer survivors some guidance on what they ... Karen Syrjala, director of biobehavioral sciences and co-director of ... Center in Seattle, touches upon both the lingering physical ...
... Carolina (UNC) researchers report in the November issue of ... diagnostic testing are overused in treating chronic neck pain. ... for neck pain, such as therapeutic exercise. According to ... effectiveness of therapeutic exercise in treating chronic neck pain ...
... not considered effective treatment for KRAS (a gene)-mutated metastatic ... cancer not responding to chemotherapy and a certain variation ... longer overall and progression-free survival than patients with other ... issue of JAMA . "Recent retrospective ...
Cached Medicine News:Health News:Teens Should Get Meningitis Booster Shot: CDC Panel 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 3Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: